About this Journal Submit a Manuscript Table of Contents
Journal of Nanotechnology
Volume 2013 (2013), Article ID 346581, 12 pages
http://dx.doi.org/10.1155/2013/346581
Review Article

Increasing Possibilities of Nanosuspension

Department of Pharmacy, Stamford University Bangladesh, 51 Siddeswari Road, Dhaka 1217, Bangladesh

Received 31 December 2012; Revised 10 March 2013; Accepted 18 March 2013

Academic Editor: Carlos R. Cabrera

Copyright © 2013 Kumar Bishwajit Sutradhar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Morrow, R. Bawa, and C. Wei, “Recent advances in basic and clinical nanomedicine,” Medical Clinics of North America, vol. 91, no. 5, pp. 805–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Sahoo, S. Parveen, and J. J. Panda, “The present and future of nanotechnology in human health care,” Nanomedicine, vol. 3, no. 1, pp. 20–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ramsden, “What is nanotechnology?” in Nanotechnology: An Introduction, pp. 1–14, Elsevier, New York, NY, USA, 2011.
  4. V. S. W. Chan, “Nanomedicine: an unresolved regulatory issue,” Regulatory Toxicology and Pharmacology, vol. 46, no. 3, pp. 218–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. Freitas, “What is nanomedicine?” Nanomedicine, vol. 1, no. 1, pp. 2–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Prabhakar and K. B. Krishna, “A review on nanosuspensions in drug delivery,” International Journal of Pharma and Bio Sciences, vol. 2, no. 1, pp. 549–558, 2011.
  7. J. Chingunpituk, “Nanosuspension technology for drug delivery,” Walailak Journal of Science & Technolog, vol. 4, no. 2, pp. 139–153, 2007.
  8. B. E. Rabinow, “Nanosuspensions in drug delivery,” Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 785–796, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Liu, X. Rong, J. Laru et al., “Nanosuspensions of poorly soluble drugs: preparation and development by wet milling,” International Journal of Pharmaceutics, vol. 411, no. 1-2, pp. 215–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. H. M. Ibrahim, H. R. Ismail, A. E. A. Lila, et al., “Formulation and optimization of ocular poly-D, L-lactic acid nano drug delivery system of amphotericin-B using box behnken design,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 2, pp. 342–349, 2012.
  11. V. B. Patravale, A. A. Date, and R. M. Kulkarni, “Nanosuspensions: a promising drug delivery strategy,” Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 827–840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Banavath, K. S. Raju, M. T. Ansari, M. S. Ali, and G. Pattnaik, “Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs,” International Journal of Pharmaceutical Sciences and Research, vol. 1, no. 9, pp. 1–11, 2010.
  13. G. A. Reddy and Y. Anilchowdary, “Nanosuspension technology: a review,” IJPI’s Journal of Pharmaceutics and Cosmetology, vol. 2, no. 8, pp. 47–52, 2012.
  14. X. Zhang, Q. Xia, and N. Gu, “Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method,” Drug Development and Industrial Pharmacy, vol. 32, no. 7, pp. 857–863, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Wongmekiat, Y. Tozuka, T. Oguchi, and K. Yamamoto, “Formation of fine drug particles by cogrinding with cyclodextrins. I. The use of β-cyclodextrin anhydrate and hydrate,” Pharmaceutical Research, vol. 19, no. 12, pp. 1867–1872, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Itoh, A. Pongpeerapat, Y. Tozuka, T. Oguchi, and K. Yamamoto, “Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS,” Chemical and Pharmaceutical Bulletin, vol. 51, no. 2, pp. 171–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. G. P. Kumar and K. G. Krishna, “Nanosuspensions: the solution to deliver hydrophobic drugs,” International Journal of Drug Delivery, vol. 3, no. 4, pp. 546–557, 2011.
  18. A. Vaghela, M. Jain, H. Limbachiya, and D. P. Bharadia, “Nanosuspension technology,” International Journal of Universal Pharmacy and Life Sciences, vol. 2, no. 2, pp. 306–317, 2012.
  19. J. P. Sylvestre, M. C. Tang, A. Furtos, G. Leclair, M. Meunier, and J. C. Leroux, “Nanonization of megestrol acetate by laser fragmentation in aqueous milieu,” Journal of Controlled Release, vol. 149, no. 3, pp. 273–280, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. McMillan, E. Batrakova, and H. E. Gendelman, “Cell delivery of therapeutic nanoparticle,” in Progress in Molecular Biology and Translational Science, vol. 104, pp. 571–572, Elsevier, New York, NY, USA, 2011.
  21. R. H. Müller and K. Peters, “Nanosuspensions for the formulation of poorly soluble drugs I: preparation by a sizereduction technique,” International Journal of Pharmaceutics, vol. 160, pp. 229–237, 1998.
  22. B. W. Müller and R. H. Müller, “Particle size analysis of latex suspensions and microemulsions by photon correlation spectroscopy,” Journal of Pharmaceutical Science, vol. 73, no. 7, pp. 915–918, 1984.
  23. R. H. Müller and B. H. L. Böhm, “Emulsions and nanosuspensions for the formulation of poorly soluble drugs,” in Nanosuspensions, R. H. Müller, S. Benita, and B. H. L. Böhm, Eds., pp. 149–174, Medpharm Scientific Publishers, Stuttgart, Germany, 1998.
  24. R. H. Müller and M. J. Grau, “Increase of dissolution velocity and solubility of poorly water soluble drugs as nanosuspension,” in Proceedings of the World Meeting APGI/APV, vol. 2, pp. 623–624, Paris, France, 1998.
  25. T. R. Shanthakumar, S. Prakash, R. M. Basavraj, et al., “Comparative pharmacokinetic data of DRF-4367 using nanosuspension and HP_CD formulation. Proceedings of the International Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems,” B. V. Patel Educational Trust and B. V. Patel PERD Centre, vol. 5, abstract 55, p. 75, 2004.
  26. R. H. Müller and C. Jacobs, “Production and characterization of a budesonide nanosuspension for pulmonary administration,” Pharmaceutical Ressearch, vol. 19, pp. 189–194, 2002.
  27. T. Blunk, D. F. Hochstrasser, J. C. Sanchez, B. W. Muller, and R. H. Muller, “Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis,” Electrophoresis, vol. 14, no. 12, pp. 1382–1387, 1993. View at Scopus
  28. T. Blunk, M. Lück, A. Calvör, et al., “Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 42, pp. 262–268, 1996.
  29. M. Lück, W. Schroder, S. Harnisch, et al., “Identification of plasma proteins facilitated by enrichment on particulate surfaces: analysis by two-dimensional electrophoresis and N-terminal microsequencing,” Electrophoresis, vol. 18, pp. 2961–2967, 1997.
  30. M. Lück, B. R. Paulke, W. Schröder, T. Blunk, and R. H. Müller, “Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics,” Journal of Biomedical Materials Research, vol. 39, no. 3, pp. 478–485, 1997.
  31. R. H. Müller, “Differential opsonization: a new approach for the targeting of colloidal drug carriers,” Archiv der Pharmazie, vol. 322, p. 700, 1989.
  32. K. H. Wallis and R. H. Müller, “Determination of the surface hydrophobicity of colloidal dispersions by mini-hydrophobic interaction chromatography,” Pharmazeutische Industrie, vol. 55, pp. 1124–1128, 1993.
  33. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Kayser, “Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 253–256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Peters, S. Leitzke, J. E. Diederichs et al., “Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 1, pp. 77–83, 2000. View at Scopus
  36. B. E. Rabinow, “Nanosuspensions for parenteral delivery,” in Nanoparticulate Drug Delivery Systems, pp. 33–49, Informa Healthcare, London, UK, 2007.
  37. D. Zheng, Y. Wang, D. Zhang et al., “In vitro antitumor activity of silybin nanosuspension in PC-3 cells,” Cancer Letters, vol. 307, no. 2, pp. 158–164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Wu, J. Zhang, and W. Watanabe, “Physical and chemical stability of drug nanoparticles,” Advanced Drug Delivery Reviews, vol. 63, no. 6, pp. 456–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. All trans Retinoic Acid, http://www.thehamner.org/docs/pbpk_11/Day3.Exercise1.ATRA.pdf.
  40. London Cancer New Drugs Group-APC/DTC Briefing, “Mitotane for the adjuvant treatment of adrenocortical carcinoma,” September 2011, http://www.nelm.nhs.uk/en/Download/?file%3DMDs3NjY0MTM7L3VwbG9hZC9QaXJmZW5pZG9uZV9EZWMgMjAxMS5wZGY_.pdf.
  41. X. Pu, J. Sun, M. Li, and Z. He, “Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs,” Current Nanoscience, vol. 5, no. 4, pp. 417–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Peters, S. Leitzke, J. E. Diederichs et al., “Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 1, pp. 77–83, 2000. View at Scopus
  43. J. M. Tam, J. T. McConville, R. O. Williams, and K. P. Johnston, “Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution,” Journal of Pharmaceutical Sciences, vol. 97, no. 11, pp. 4915–4933, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Calne, “Cyclosporine as a milestone in immunosuppression,” Transplantation Proceedings, vol. 36, no. 2, pp. 13S–15S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Das and P. K. Suresh, “Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B,” Nanomedicine, vol. 7, no. 2, pp. 242–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. H. P. Thakkar, B. V. Patel, and S. P. Thakkar, “Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement,” Journal of Pharmacy and Bioallied Sciences, vol. 3, no. 3, pp. 426–434, 2011.
  47. V. M. Pandya, J. K. Patel, and D. J. Patel, “Effect of different stabilizer on the formulation of simvastatin nanosuspension prepared by nanoprecipitation technique,” Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 1, no. 4, pp. 910–917, 2010. View at Scopus
  48. L. Zhao, Y. Wei, Y. Yu, and W. Zheng, “Polymer blends used to prepare nifedipine loaded hollow microspheres for a floating-type oral drug delivery system: In vitro evaluation,” Archives of Pharmacal Research, vol. 33, pp. 443–450, 2010.
  49. G. P. Kumar and K. G. Krishna, “Nanosuspensions: the solution to deliver hydrophobic drugs,” International Journal of Drug Delivery, vol. 3, pp. 546–557, 2011.
  50. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amighi, “Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine,” International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. Bhavna, F. J. Ahmad, R. K. Khar, S. Sultana, and A. Bhatnagar, “Techniques to develop and characterize nanosized formulation for salbutamol sulfate,” Journal of Materials Science: Materials in Medicine, vol. 20, supplement 1, pp. S71–S76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Piao, N. Kamiya, A. Hirata, T. Fujii, and M. Goto, “A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium,” Pharmaceutical Research, vol. 25, no. 4, pp. 896–901, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Lei, Z. Dianrui, C. Minghui, Z. Tingting, and W. Shumei, “Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement,” Drug Development and Industrial Pharmacy, vol. 33, no. 12, pp. 1332–1339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Qi, D. Zhang, X. Xu, et al., “Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line,” International Journal of Nanomedicine, vol. 7, pp. 1793–1804, 2012.
  55. R. Ravichandran, “Preparation and characterization of albendazole nanosuspensions for oral delivery,” International Journal of Green Nanotechnology, vol. 2, no. 1, pp. B1–B24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Dhanapal and J. V. Ratna, “Nanosuspensions technology in drug delivery-a review,” International Journal of Pharmacy Review & Research, vol. 2, no. 1, pp. 46–52, 2012.
  57. R. Shegokar, K. K. Singh, and R. H. Müller, “Nevirapine nanosuspension: comparative investigation of production methods,” Nanotechnology Development, vol. 1, no. e4, pp. 16–22, 2011.
  58. “Enhanced Analgesic activity of Polymeric or Lipidic Nanosuspension of Naproxen,” http://www.aapsj.org/abstracts/AM_2002/AAPS2002-002064.pdf.
  59. P. Lakshmi and G. A. Kumar, “Nanosuspension technology: a review,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, supplement 4, pp. 35–40, 2010.
  60. E. Merisko-Liversidge and G. G. Liversidge, “Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology,” Advanced Drug Delivery Reviews, vol. 63, no. 6, pp. 427–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. O. Kayser, “Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 253–256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Scholer, K. Krause, O. Kayser, et al., “Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis,” Antimicrobial Agents and Chemotherapy, vol. 45, pp. 1771–1779, 2001.
  63. K. K. Jain, “Miscellaneous applications,” in The Handbook of Nanomedicine, p. 325, Humana Press, New York, NY, USA, 2008.
  64. L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma, “Preparation of a chemically stable quercetin formulation using nanosuspension technology,” International Journal of Pharmaceutics, vol. 404, no. 1-2, pp. 231–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Ojewole, I. Mackraj, P. Naidoo, and T. Govender, “Exploring the use of novel drug delivery systems for antiretroviral drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 3, pp. 697–710, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. R. H. Müller and C. M. Keck., “Twenty years of drug nanocrystals: where are we, and where do we go?” European Journal of Pharmaceutics and Biopharmaceutics, vol. 80, pp. 1–3, 2012.
  67. J. M. Tam, J. D. Engstrom, D. Ferrer, R. O. Williams, and K. P. Johnston, “Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers,” Journal of Pharmaceutical Sciences, vol. 99, no. 7, pp. 3150–3165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. J. D. Engstrom, J. M. Tam, M. A. Miller, R. O. Williams, and K. P. Johnston, “Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers,” Pharmaceutical Research, vol. 26, no. 1, pp. 101–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. P. P. Constantinides, M. V. Chaubal, and R. Shorr, “Advances in lipid nanodispersions for parenteral drug delivery and targeting,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 757–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. Z. Bourezg, S. Bourgeois, S. Pressenda, T. Shehada, and H. Fessi, “Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods,” Colloids and Surfaces A, vol. 413, no. 5, pp. 191–199, 2012.
  71. N. Saffoon, R. Uddin, N. H. Huda, and K. B. Sutradhar, “Enhancement of oral bioavailability and solid dispersion: a review,” Journal of Applied Pharmaceutical Science, vol. 1, no. 7, pp. 13–20, 2011.